ReveraGen releases positive data for Duchenne drug vamorolone
ReveraGen BioPharma today announced positive study data with vamorolone in patients with Duchenne muscular dystrophy (DMD). Data from the six-month Phase IIa-extension study (VBP15-003) published in Neurology demonstrated dose-related improvement of muscle function in patients with DMD treated with vamorolone.
The news had a positive impact on Swiss biotech Santhera Pharmaceuticals (SIX: SANN), which has an option on vamorolone, and saw its shares leap 11.5% to 14.15 Swiss francs in early trading.
Eric Hoffman, chief executive of ReveraGen, commented: “The six-month extension study in comparison to natural history study data demonstrated dose-dependent improvement in timed function tests. Vamorolone was reported to be safe and well tolerated up to the highest dose tested (6.0mg/kg/day). Based on these data, vamorolone has potential to replace standard corticosteroids currently used in patients with DMD.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze